California moves forward with making biosimilar insulin
The state has entered a contract with generic drugmaker Civica to make insulin products that are interchangeable with those of Novo Nordisk, Sanofi, and Eli Lilly.
by albert rønning-andersson, translated by daniel pedersen
The state of California will soon be able to produce its own cheaper insulin products based off of those from for example Novo Nordisk, Sanofi, and Eli Lilly.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi follows Lilly, Novo in cutting insulin prices
For subscribers
Joe Biden applauds Novo Nordisk for insulin price reductions
For subscribers
